Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GE And Shanghai Pulmonary Hospital Jointly Develop Diagnostics For Pneumoconiosis

This article was originally published in PharmAsia News

Executive Summary

GE China's R&D center recently signed an agreement with Shanghai Pulmonary Hospital to jointly develop CAD techniques which can automatically screen and distinguish diseased and normal human thoracic X-ray images. This technique, which greatly decreases the time and cost for pneumoconiosis checkup, will make examinations accessible to more workers, helping in the prevention and treatment of China's leading occupational disease. Current methods are costly and not very effective, resulting in millions of at-risk local workers unscreened. The two partners will also apply the new technique to the field of digital X-ray and simulation X-ray. (Click here for more - Chinese language)

You may also be interested in...



Brinavess Rejected By Advisory Cmte., Leaving US FDA To Mull Lifting Clinical Hold On Correvio's AFib Drug

Cardiovascular and Renal Drugs Advisory Committee voted 11-2 against approval for Correvio's atrial fibrillation drug Brinavess over cardiovascular safety concerns; the agency would have to lift the long-standing  clinical hold on the drug before the company can do any further study in humans.

Biologic Exclusivity Provision In USMCA Is Boon To Generics Industry; BIO Is 'Tremendously Worried'

Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.

Kite Readies A Second CAR-T For Filing As CD19 Competition Grows

The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year. 

UsernamePublicRestriction

Register

SC068616

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel